SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on April 17, 2002; DOI 10.1182/blood-2002-01-0006. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-01-0006v1 100/1/52    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Coustan-Smith, E. Articles by Campana, D. Search for Related Content PubMed PubMed Citation Articles by Coustan-Smith, E. Articles by Campana, D. Related Collections Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 July 2002, Vol. 100, No. 1, pp. 52-58 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia Elaine Coustan-Smith, Jose Sancho, Frederick G. Behm, Michael L. Hancock, Bassem I. Razzouk, Raul C. Ribeiro, Gaston K. Rivera, Jeffrey E. Rubnitz, John T. Sandlund, Ching-Hon Pui, and Dario Campana From the Departments of Hematology-Oncology, Pathology, Biostatistics, St Jude Children's Research Hospital; and the University of Tennessee, Memphis, TN. Early clearance of leukemic cells is a favorable prognostic indicator in childhood acute lymphoblastic leukemia (ALL). However, identification of residual leukemic cells by their morphologic features is subjective and lacks sensitivity. To improve estimates of leukemia clearance, we applied flow cytometric techniques capable of detecting 1 leukemic cell in 10 000 or more normal cells and prospectively measured residual leukemia in bone marrow samples collected on day 19 of remission-induction chemotherapy from 248 children with newly diagnosed ALL. In 134 samples (54.0%), we identified at least 0.01% leukemic cells (0.01%-< 0.1% in 51 samples [20.6%], 0.1%-< 1% in 36 [14.5%], and  1% in 47 [19.0%]). Among 110 children treated within a single chemotherapy program, the 5-year mean ± SE cumulative incidence of relapse or failure to achieve remission was 32.2% ± 6.5% for the 59 patients with 0.01% residual leukemic cells or greater on day 19 and 6.0% ± 3.4% for the 51 patients with less than 0.01% leukemic cells (P < .001). The prognostic value of day-19 bone marrow status defined by flow cytometry was superior to that defined by morphologic studies and remained significant after adjustment for other clinical and biologic variables. Lack of detectable leukemic cells on day 19 was more closely associated with relapse-free survival than was lack of detectable residual disease at the end of remission induction (day 46). Thus, approximately half of the children with ALL achieve profound clearance of leukemic cells after 2 to 3 weeks of remission-induction chemotherapy, and these patients have an excellent treatment outcome. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T. Muzzafar, L. J. Medeiros, S. A. Wang, A. Brahmandam, D. A. Thomas, and J. L. Jorgensen Aberrant Underexpression of CD81 in Precursor B-Cell Acute Lymphoblastic Leukemia: Utility in Detection of Minimal Residual Disease by Flow Cytometry Am J Clin Pathol, November 1, 2009; 132(5): 692 - 698. [Abstract] [Full Text] [PDF] G. Basso, M. Veltroni, M. G. Valsecchi, M. N. Dworzak, R. Ratei, D. Silvestri, A. Benetello, B. Buldini, O. Maglia, G. Masera, et al. Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow J. Clin. Oncol., November 1, 2009; 27(31): 5168 - 5174. [Abstract] [Full Text] [PDF] C.-H. Pui Toward a Total Cure for Acute Lymphoblastic Leukemia J. Clin. Oncol., November 1, 2009; 27(31): 5121 - 5123. [Full Text] [PDF] C. A. Scrideli, J. G. Assumpcao, M. A. Ganazza, M. Araujo, S. R. Toledo, M. L. M. Lee, E. Delbuono, A. S. Petrilli, R. P. Queiroz, A. Biondi, et al. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups Haematologica, June 1, 2009; 94(6): 781 - 789. [Abstract] [Full Text] [PDF] J. Irving, J. Jesson, P. Virgo, M. Case, L. Minto, L. Eyre, N. Noel, U. Johansson, M. Macey, L. Knotts, et al. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting; Haematologica, June 1, 2009; 94(6): 870 - 874. [Abstract] [Full Text] [PDF] F. Tucci and M. Arico Treatment of pediatric acute lymphoblastic leukemia Haematologica, August 1, 2008; 93(8): 1124 - 1128. [Full Text] [PDF] M. J. Borowitz, M. Devidas, S. P. Hunger, W. P. Bowman, A. J. Carroll, W. L. Carroll, S. Linda, P. L. Martin, D. J. Pullen, D. Viswanatha, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study Blood, June 15, 2008; 111(12): 5477 - 5485. [Abstract] [Full Text] [PDF] C. Oudot, M.-F. Auclerc, V. Levy, R. Porcher, C. Piguet, Y. Perel, V. Gandemer, M. Debre, C. Vermylen, B. Pautard, et al. Prognostic Factors for Leukemic Induction Failure in Children With Acute Lymphoblastic Leukemia and Outcome After Salvage Therapy: The FRALLE 93 Study J. Clin. Oncol., March 20, 2008; 26(9): 1496 - 1503. [Abstract] [Full Text] [PDF] A. C. Rawstron, A. Orfao, M. Beksac, L. Bezdickova, R. A. Brooimans, H. Bumbea, K. Dalva, G. Fuhler, J. Gratama, D. Hose, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders Haematologica, March 1, 2008; 93(3): 431 - 438. [Abstract] [Full Text] [PDF] J. L. Fuster, M. Bermudez, A. Galera, M. E. Llinares, D. Calle, and F. J. Ortuno Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia Haematologica, December 1, 2007; 92(12): 1723 - 1724. [Abstract] [Full Text] [PDF] C. Flotho, E. Coustan-Smith, D. Pei, C. Cheng, G. Song, C.-H. Pui, J. R. Downing, and D. Campana A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia Blood, August 15, 2007; 110(4): 1271 - 1277. [Abstract] [Full Text] [PDF] F. R. Appelbaum, D. Rosenblum, R. J. Arceci, W. L. Carroll, P. P. Breitfeld, S. J. Forman, R. A. Larson, S. J. Lee, S. B. Murphy, S. O'Brien, et al. End points to establish the efficacy of new agents in the treatment of acute leukemia Blood, March 1, 2007; 109(5): 1810 - 1816. [Abstract] [Full Text] [PDF] T. Raff, N. Gokbuget, S. Luschen, R. Reutzel, M. Ritgen, S. Irmer, S. Bottcher, H.-A. Horst, M. Kneba, D. Hoelzer, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials Blood, February 1, 2007; 109(3): 910 - 915. [Abstract] [Full Text] [PDF] A. Reiter Diagnosis and Treatment of Childhood Non-Hodgkin Lymphoma Hematology, January 1, 2007; 2007(1): 285 - 296. [Abstract] [Full Text] [PDF] H. M. Lazarus and S. Luger Which Patients with Adult Acute Lymphoblastic Leukemia Should Undergo a Hematopoietic Stem Cell Transplantation? Case-Based Discussion Hematology, January 1, 2007; 2007(1): 444 - 452. [Abstract] [Full Text] [PDF] C. Flotho, E. Coustan-Smith, D. Pei, S. Iwamoto, G. Song, C. Cheng, C.-H. Pui, J. R. Downing, and D. Campana Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2 Blood, August 1, 2006; 108(3): 1050 - 1057. [Abstract] [Full Text] [PDF] E. Coustan-Smith, R. C. Ribeiro, P. Stow, Y. Zhou, C.-H. Pui, G. K. Rivera, F. Pedrosa, and D. Campana A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome Blood, July 1, 2006; 108(1): 97 - 102. [Abstract] [Full Text] [PDF] B. K. Zehentner, W. Fritschle, T. Stelzer, K. M. Ghirardelli, K. Hunter, C. Wentzel, R. Bennington, C. L. Hansen, D. Myerson, M. Kalnoski, et al. Minimal Disease Detection and Confirmation in Hematologic Malignancies: Combining Cell Sorting with Clonality Profiling Clin. Chem., March 1, 2006; 52(3): 430 - 437. [Abstract] [Full Text] [PDF] M. Bruggemann, T. Raff, T. Flohr, N. Gokbuget, M. Nakao, J. Droese, S. Luschen, C. Pott, M. Ritgen, U. Scheuring, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia Blood, February 1, 2006; 107(3): 1116 - 1123. [Abstract] [Full Text] [PDF] T. Haferlach, A. Kohlmann, S. Schnittger, M. Dugas, W. Hiddemann, W. Kern, and C. Schoch Global approach to the diagnosis of leukemia using gene expression profiling Blood, August 15, 2005; 106(4): 1189 - 1198. [Abstract] [Full Text] [PDF] S. J. Laughton, L. J. Ashton, E. Kwan, M. D. Norris, M. Haber, and G. M. Marshall Early Responses to Chemotherapy of Normal and Malignant Hematologic Cells Are Prognostic in Children With Acute Lymphoblastic Leukemia J. Clin. Oncol., April 1, 2005; 23(10): 2264 - 2271. [Abstract] [Full Text] [PDF] C.-H. Pui, J. T. Sandlund, D. Pei, D. Campana, G. K. Rivera, R. C. Ribeiro, J. E. Rubnitz, B. I. Razzouk, S. C. Howard, M. M. Hudson, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital Blood, November 1, 2004; 104(9): 2690 - 2696. [Abstract] [Full Text] [PDF] N. J. Winick, W. L. Carroll, and S. P. Hunger Childhood Leukemia -- New Advances and Challenges N. Engl. J. Med., August 5, 2004; 351(6): 601 - 603. [Full Text] [PDF] C.-H. Pui, M. Schrappe, R. C. Ribeiro, and C. M. Niemeyer Childhood and Adolescent Lymphoid and Myeloid Leukemia Hematology, January 1, 2004; 2004(1): 118 - 145. [Abstract] [Full Text] [PDF] M.-B. Vidriales, J. J. Perez, M. C. Lopez-Berges, N. Gutierrez, J. Ciudad, P. Lucio, L. Vazquez, R. Garcia-Sanz, M. C. del Canizo, J. Fernandez-Calvo, et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value Blood, June 15, 2003; 101(12): 4695 - 4700. [Abstract] [Full Text] [PDF] J Moppett, G A A Burke, C G Steward, A Oakhill, and N J Goulden The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia J. Clin. Pathol., April 1, 2003; 56(4): 249 - 253. [Abstract] [Full Text] [PDF] W. L. Carroll, D. Bhojwani, D.-J. Min, E. Raetz, M. Relling, S. Davies, J. R. Downing, C. L. Willman, and J. C. Reed Pediatric Acute Lymphoblastic Leukemia Hematology, January 1, 2003; 2003(1): 102 - 131. [Abstract] [Full Text] [PDF] E. Coustan-Smith, J. Sancho, M. L. Hancock, B. I. Razzouk, R. C. Ribeiro, G. K. Rivera, J. E. Rubnitz, J. T. Sandlund, C.-H. Pui, and D. Campana Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia Blood, September 18, 2002; 100(7): 2399 - 2402. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020